Oak Thistle LLC Buys Shares of 48,501 Boston Scientific Corporation $BSX

Oak Thistle LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 48,501 shares of the medical equipment provider’s stock, valued at approximately $4,735,000. Boston Scientific comprises about 0.7% of Oak Thistle LLC’s holdings, making the stock its 8th biggest position.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new stake in Boston Scientific during the second quarter valued at approximately $2,089,937,000. Edgewood Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth $746,655,000. Bessemer Group Inc. increased its position in shares of Boston Scientific by 14,391.8% during the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after purchasing an additional 2,899,653 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after purchasing an additional 2,545,381 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after purchasing an additional 1,664,108 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 target price on shares of Boston Scientific in a research report on Wednesday, October 22nd. Leerink Partners boosted their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Robert W. Baird increased their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. UBS Group lifted their target price on shares of Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Finally, Wells Fargo & Company upped their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $125.15.

Insider Buying and Selling

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 143,095 shares of company stock valued at $14,228,950 over the last 90 days. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $92.93 on Wednesday. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The business’s 50 day moving average price is $98.70 and its 200 day moving average price is $101.42. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The firm has a market cap of $137.76 billion, a P/E ratio of 49.70, a P/E/G ratio of 1.86 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. Boston Scientific’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period last year, the firm posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.